Adults 45 to 74, any sex, with Chronic Kidney Diseases or Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Vascular Endothelial Function at 12 MonthsPrimary· 12 months
Brachial artery flow-mediated dilation, changed in diameter in brachial artery in response to shear stress
Group
Value
95% CI
Curcumin
-0.1
-1.5 – 1.5
Placebo
-0.7
-2.1 – 1.1
Large Artery StiffnessSecondary· 12 months
Aortic pulse wave velocity
Group
Value
95% CI
Curcumin
0.28
± 2.4
Placebo
0.36
± 4.2
Cognitive FunctionSecondary· 12 months
NIH toolbox battery- Executive Function Age-Corrected Standard Score is reported (T-score): This score compares the score of the test-taker to those in the NIH Toolbox nationally representative normative sample at the same age, where a score of 100 indicates performance that was at the national average for the test-taking participant's age. Age-corrected standard scores were derived separately for children (ages 3-17) and adults (ages 18-85). A score of 115 or 85, for example, would indicate that the participant's performance is 1 SD above or below the national average, respectively, when comp
Group
Value
95% CI
Curcumin
2.62
± 9
Placebo
2.25
± 9.5
Adverse events — posted to ClinicalTrials.gov
Time frame: 12 MONTHS.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The proposed research is clinical study evaluating the therapeutic benefits of curcumin on vascular function in patients with chronic kidney disease (CKD). The study aims to establish that curcumin will improve endothelial function and reduce large artery stiffness by reducing oxidative stress and in conjunction with lowering markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in patients with CKD.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07436130 — Curcumin in Critically Ill Patients With Sepsis
· NA
· not yet recruiting
NCT07251985 — Cognitive Effects of Bioavailable Curcumin
· Phase 2
· not yet recruiting
NCT07379177 — Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human
· NA
· not yet recruiting
NCT07523256 — Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
· NA
· completed
NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
· EARLY_PHASE1
· recruiting
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
· Phase 2
· recruiting
NCT07358572 — Eye-Brain-Kidney in CKD
· recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease
· NA
· recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
· NA
· recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
· NA
· recruiting
Other Diana Jalal trials
Trials by the same sponsor.
NCT06526494 — Metformin and Vascular Function in Prediabetes
· Phase 2
· withdrawn
NCT03597568 — Resveratrol and Vascular Function in CKD
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Diana Jalal
Last refreshed: 8 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03223883.